## Abstract Patients with newly diagnosed acute myeloid leukaemia (AML) are increasingly being enrolled in clinical trials sponsored by pharmaceutical companies or the National Cancer Institute. These trials routinely exclude patients who are less likely to respond (LLTR), e.g. those with Zubrod pe
Immunomonitoring and prognostic relevance of neutrophils in clinical trials
โ Scribed by Donskov, Frede
- Book ID
- 119939984
- Publisher
- Elsevier Science
- Year
- 2013
- Tongue
- English
- Weight
- 302 KB
- Volume
- 23
- Category
- Article
- ISSN
- 1044-579X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Adjuvant therapy of breast cancer has evolved over the past 15 years from an interesting clinical experiment to the standard of care for many patients. The toxicities of different treatments vary from those with minimal side effects, such as tamoxifen, to those with potentially lifethreatening side
Response to treatment is the most important prognostic factor in children undergoing treatment for acute lymphoblastic leukemia. Factors that interfere with the pharmacokinetic determinants of anti-leukemic compounds may cause a decreased activity of one or more of the drugs included in the treatmen